Member Info for Fardistanthills

It should be possible to take up your Open Offer entitlement outside an ISA even though it is showing within it, and you cannot introduce more cash. My Offer entitlement was all within my ii ISA but I cannot subscribed futher to it as my current years ISA subsciption has been made already, with a different provider. Since I do have some cash in the Avacta ii ISA I was able to take up about 25% of my entitlement within it and then ii arranged for the rest to be taken up outside in my ii Trading A/C - they were very quick getting this done, it is now all arranged - full marks to them. And no fees to pay.

Mines a fat rascal!

Thanks Myles, appreciate you sharing this.

Mr A - I'm talking LFD Covid test - pre suspension - when there was some hope that they had a product that might revolutionise the UK dignostics industry (which affimer based LFDs still potentially will). There was little 'mainstream' mention of this breakthrough possibility, though there was much discussion of the need for it here on the LSE board. And of course with hindsight it would have been premature. I think we can maybe assume that AS actually played it well, or was lucky - biting his tongue and keeping schtum. But thats all best left in the past. Better things lie ahead and hopefully soon,

By and large a good thread ;-) I’m also looking ahead with great interest as to how they deliver the good news story (OK, I'm assuming it'll to be good news). Obviously an RNS and I agree, longer term peer reviewed papers - and a lot in the specialist medical press. No doubt AS will present as well. He's a good bio-science communicator, gets the principles over without being banal. It'll be interesting to see whether they get the story into the mainstream. Striking headlines in the likes of Mail-online - "Breakthrough in Cancer Treatment" "Red Devil Conquered". I hope they’re getting advice on how to make this happen – they’ve not shone here previously. It’ll be interesting to see whether the low cost side of it gets picked up too – a well-established drug with a ‘simple’ modification that will bring relief to thousands whilst keeping medical costs down. It’s obviously what’s happening behind the scenes that matters from an investment stance and ultimately for the development of the pro-drug platform. All of which has hopefully has been ongoing awhile - some hard ball deal making, resulting in a fantastic licencing agreement - something which AS does seem to do well. That’s an announcement that would get picked up and run hard with in the bio-pharma investment community. We can but dream!

Hi Monkswood, below is from the 23rd June AGM Business Update - slide 15

Therapeutics Research Day in November 2022 – date to be announced
Planning a Diagnostics Research Day in Q1 2023.

I've not yet seen anything giving firm dates

Muller12 - and this is not just directed to you, but to others on here who have a similar degree of recall and maybe also medical/scientific knowledge much beyond mine.

So - it never ceases to amaze me how well informed so many of you are. How do you manage to remember what was said 18 minutes into a 7 month old interview! Wonderful - and really appreciated. And as I say, its not just Muller, there are others who quite often pop up posting such nuggets.

Thanks, I salute you all!

Also at the opening was Professor Udai Banerji, Deputy Director of Drug Development at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust who "is working with many industry partners to trial their innovative new drugs" - including with Avacta on AVA600. And it was at the Royal Marsden last summer that the first patient received their first dose of AVA6000. Thanks vrmnd.

Crossed in the post ;)

Thanks. Paul Hills is quite a knowledgeable " independent" (and enthusiastic!) reporter -knowledgeable in that as I recall he suffers from a rather debilitating condition himself.

Oozing confidence - everything coming together for a big reveal at the Science Day, and in an strong negotiating position net cash wise to pull off an impressive licencing deal. Once one deal is done the realisation will dawn that AVCT has a platform therapy.

"Avacta seem to have unwittedly got involved with a nest of cowboys. All the more reason, I think, to work with an established diagnostics company in future for development, approval, manufacture and marketing." Absolutley. Yet ironic that thanks to M19 and the perceived LFT opportunity, but before getting drawn into the thick of this mess, AVCT were able to raise funds sufficient to get AVA6k off the ground and recover.

Just to add my thanks J_T for a realy great bit of work. Plus a bit of speculation on RAH004's follow up - re the US sites not yet having been announced as initiating.

Could this to be do with having got ODD from the FDA for STS? If indeed the results coming out of the UK P1a trials are so clear cut, then as you say RAH, maybe they have decided that extending P1a to include US sites is no longer required. It adds no value. Maybe also they are no longer being considered for P1b? Perhaps instead these US sites are now being re-purposed as it were and that patients in the US will be recruited for trials specifically to prove up AVA6k for SCS ODD use? Presumably this could be done on an accelarated timescale using FDA procedure compared with what is prescribed in P1b?

All speculation on my part and based purely on my far from perfect understanding of such things!

Thanks D-G. I stand corrected - said the man in the orthopedic shoes. Editorialy corrected that is ;)

LSE seems to work in exactly the same way as the (not) much missed News of the World. All human life was there - "World War II Bomber Found on the Moon" - "Eighty Three Year Old Grannie Gives Birth To Chimpanzee" Anything to get the circulation up and eyeballs across ads. All human is certainly here too at times. Especially it seems when there is a lull in actual stuff from Avacta. Quite a coincidence that when a couple longish threads develop with more knowledgeable posters getting their teeth into something interesting, or an RNS appears, the volume of weirdo traffic fades. Or maybe it is just me being very selective in what I read.

Or to adapt the words of James Goldsmith - the bandwagon is not yet quite in sight!

I'm with gmcc, who's with Donkeyeeyore, who's with Tom. Quite a few of us long term holders no doubt started out as so called super rampers. Anyway its good to see some fresh enthusiasm - keeps our spirits up. And I do agree with those - like Tom - who reckon AVCT's prospects are very rosy,

Thanks for posting - interesting to see a bit of the personal, the personality - what gets under his skin, so to speak

"Why would they ask for more money before they release data when they could release data and get it a lot easier”. I couldn’t agree more either. But I would imagine anyway, given all that AS must know about how well AVA6k is working, they now have the confidence to already have a good handle on how they are going to do their next fund raise. I don't think they will want someone coming along with any sort of early BO offer either, and they will want to pre-empt this. Any such event at this stage this would be totally underwhelming and fail to recognise the huge long term potential. I suspect that if a large corporate pharma got hold of AVCT a lot of the promise and the bio-entrepreneurship bound up in the company would be lost. Its potential will only be truly realised if AVCT stays independent and develops its therapeutics, affimers and diagnostics into the market via a licensing model. Knowing, as I am sure many here do, the tragedy that can be wrought by a cancer diagnosis, I am pleased to be invested for the long term where hopefully I am contributing to the wider good.

So... great to see today's RNS and the further progress it represents.

If I have understood things correctly, doesn't Avacta's Safety Data Monitoring Committe have the principal role here? Surely if the clinicians on this Committe see it as clinically inappropriate or unneccesary to DE above 160 then this will be the upper limit, in spite of what AS may or not think. Likewise, assuming they were in charge of the clinical decision at the time, it was this Committee that chose to advance the third dose cohort to 160mg/m2 rather than the previously planned 150?